Company intelligence / Profile preview

Azome Therapeutics

Malvern, Pennsylvania, United Statesazometherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Azome's lead drug candidate AZM-152 has shown promising results in preclinical studies across seven different models of lung inflammation. The company has entered into a CRADA with the National Center for Advancing Translational Sciences to investigate AZM-152 for preventing Bronchopulmonary Dysplasia.

Therapeutic areas: PulmonologyNephrologyInfectious Diseases
Modalities: Peptides (AZM-152)Small molecules (in development)
Industry: Biotech

Drug pipeline

1 asset

AZM-152

Preclinical

Partnerships

National Center for Advancing Translational Sciences (NCATS)

Beyond the preview

Go deeper on Azome Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Azome Therapeutics.

Explore the full profile